NHS to offer second MenB vaccine after deadly Kent outbreak
NHS to offer second MenB vaccine after deadly Kent outbreak
The National Health Service (NHS) will begin administering a second dose of the meningitis B vaccine to approximately 12,000 individuals in Kent who received their first shot during a recent outbreak. This initiative aims to bolster immunity against the disease, which claimed two lives and affected 19 others in the region. The vaccination program was launched to protect those potentially exposed, including university students and schoolchildren in the area.
Expanded eligibility and vaccination rollout
Eligibility for the second dose includes students residing in Kent’s university halls, as well as individuals who frequented a nightclub linked to the outbreak. Clinics are expected to open in Canterbury, Faversham, and Ashford, with online systems allowing appointments. NHS Kent and Medway announced that multiple sites will offer the vaccine, with booking details to be released starting Monday.
Outbreak response and public health measures
The UK Health Security Agency (UKHSA) classified the incident as a national event to facilitate resource distribution, including antibiotics. Preventative antibiotics were provided to a broader group, leading to long lines at the University of Kent over several days. The targeted program initially focused on students at local clubs before expanding to sixth form pupils at institutions with confirmed cases.
“This outbreak is unprecedented due to the rapid spread among a large number of people,” said Health Secretary Wes Streeting.
Historical context and revised strategy
A routine MenB vaccination program was introduced in the UK in 2015, targeting infants and young children. At that time, UK health advisers determined a catch-up campaign for teenagers was not economically viable. Teenagers are instead routinely given the MenACWY vaccine, which guards against four bacterial strains but excludes meningococcal group B. The recent Kent outbreak prompted Streeting to request a review of this decision by independent experts at the Joint Committee on Vaccination and Immunisation (JCVI).
